Tropifexor

Tropifexor is a drug that is currently under investigation for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). It is a farnesoid X receptor (FXR) agonist, which means it activates the FXR, a nuclear receptor that plays a crucial role in regulating bile acids, lipids, and glucose homeostasis.

Mechanism of Action

Tropifexor works by activating the farnesoid X receptor (FXR). This receptor is found in the liver, kidney, adrenal gland, and intestine, and it plays a key role in regulating bile acids, lipids, and glucose. When activated, the FXR can help to reduce the amount of fat and inflammation in the liver, which can be beneficial for people with conditions like NASH and PBC.

Clinical Trials

Tropifexor is currently in the clinical trial phase for the treatment of NASH and PBC. Early results from these trials have shown promise, with patients experiencing a reduction in liver fat and inflammation. However, more research is needed to fully understand the drug's efficacy and safety profile.

Side Effects

As with any drug, Tropifexor may cause side effects. These can include nausea, vomiting, diarrhea, and abdominal pain. It's important for patients to discuss these potential side effects with their healthcare provider before starting treatment.

See Also

• Non-alcoholic steatohepatitis
• Primary biliary cholangitis
• Farnesoid X receptor
• Clinical trial

Tropifexor Resources
Latest articles Most recent articles Ongoing trials	Wikipedia